Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Dabigatran experience in primary and secondary prevention of cardioembolic stroke

https://doi.org/10.14412/2074-2711-2013-2417

Full Text:

Abstract

The review of novel oral anticoagulants (dabigatran, rivaroxaban and apixaban) in stroke prevention and also own data of administration of dabigatran in primary and secondary prevention of ischemic stroke in 45 patients with cerebrovascular diseases are presented. Most patients received dabigatran 14 days after the first stroke associated with nonvalvular atrial fibrillation. In other cases dabigatran was used for primary prevention of stroke in patients with chronic forms of cerebrovascular diseases and nonvalvular atrial fibrillation. Dabigatran shows good tolerability and efficacy. Recurrent strokes were diagnosed in 2 patients. The reasons for these events were arterial hypertension in one case and symptomatic atherosclerotic plaque in the other case.

References

1. <div><p>Инсульт. Принципы диагностики, лечения и профилактики. Краткое руководство для врачей. Под ред. Н.В. Верещагина, М.А. Пирадова, З.А. Суслиной. М.:Интермедика, 2002;206 с.</p><p>Кардионеврология: справочное руководство с обзором клинических исследований. Под ред. З.А. Суслиной и А.В. Фонякина. М.:ИМА-ПРЕСС, 2011;264 с.</p><p>Petty G.W., Brown R.D.Jr, Whisnant J.P. et al. Ischemic stroke subtypes. A population-based study of functional outcome, survival and recurrence. Stroke 2000;31:1062—68.</p><p>Secades J. Citicoline: pharmacological and clinical review, 2010 update Rev Neurol 2011;52:551—62.</p><p>Hanna J.P., Furlan A.J. Cardiac disease and embolic sources. In: Brain ischemia: basic concepts and clinical relevance. L.R. Caplan (ed.). London etc.: SpringerVerlag, 1995.</p><p>Furie K.L., Kasner S.E., Adams R.J. et al. Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2011;42:227—76.</p><p>Singer D.E., Albers G.W., Dalen J.E. et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed.). Chest 2008;133 (Suppl 6):546S—592S.</p><p>Guidelines for Management of Ischaemic Stroke of the European Stroke Organisation, 2008 http://www.eso-stroke.org/recommendations.</p><p>Суслина З.А., Танашян М.М., Домашенко М.А. Антитромботическая терапия ишемических нарушений мозгового кровообращения. М.:МИА, 2009;224 с.</p><p>Hirsh J., Fuster V. Guide to anticoagulant therapy. Part 2: oral anticoagulants. Circulation 1994;89:1469—80.</p><p>Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993;342(8882):1255.</p><p>ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367(9526):1903—12.</p><p>Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008;47:285—95.</p><p>Инструкция по медицинскому применению препарата Прадакса® (дабигатрана этексилат) ЛП-000872-181011 и ЛП-000872-020812.</p><p>Connolly S.J., Ezekowitz M.D., Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation [published correction appears in N Engl J Med 2010;363:1877]. N Engl J Med 2009;361:1139—51.</p><p>Eikelboom J.W., Wallentin L., Connolly S.J. et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial. Circulation 2011;123:2363—72.</p><p>Connolly S.J., Ezekowitz M.D., Yusuf S. et al. Newly identified events in the RE-LY trial. N Engl J Med 2010;363:1875—76.</p><p>Hohnloser S.H., Oldgren J., Yang S. et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation 2012;125:669—76.</p><p>Uchino K., Hernandez A.V. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Int Med 2012;172:397—402.</p><p>Larsen T.B., Rasmussen L.H., Skjoth F. et al. Efficacy and safety of dabigatran etexilate and warfarin in «real world» patients with atrial fibrillation: A prospective nationwide cohort study. J Am Coll Cardiol 2013; doi:10.1016/j.jacc.2013.03.020.</p><p>Diener H.C., Connolly S.J., Ezekowitz M.D. et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial [published correction appears in Lancet Neurol. 2011;10:27]. Lancet Neurol 2010;9:1157—63.</p><p>Furie K.L., Goldstein L.B., Albers G.W. et al. Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation: A Science Advisory for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2012;43:3442—53.</p><p>Camm J., Lip G.Y.H., De Caterina R. et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart J 2012;33:2719—47.</p><p>Рекомендации РКО, ВНОА и АССХ «Диагностика и лечение фибрилляции предсердий». Вып 2, 2012.</p><p>Инструкция по медицинскому применению препарата Ксарелто® (ривароксабан) ЛП-001457-250112.</p><p>Patel M.R., Mahaffey K.W., Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883—91.</p><p>Fox K.A.A., Piccini J.P., Wojdyla D. et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011;32: 2387—94.</p><p>Connolly S.J., Eikelboom J., Joyner C. et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806—17.</p><p>European Medicines Agency. Eliquis (apixaban) film-coated tablets: EU summary of product characteristics, 2012. http://www.ema.europa.eu/docs/en_GB/document _library/EPAR_-_Product_Information/human/002148/WC50 0107728^^Государственный реестр лекарственных средств РФ. Апиксабан. Регистрационный номер ЛП-002007 от 19.02.2013.http://grls.rosminzdrav.ru/grls.asp x?s=%D0%B0%D0%BF%D0%B8%D0%BA %D1%81%D0%B0%D0%B1%D0%B0%D0% BD</p><p>Granger C.B., Alexander J.H., McMurray J.J. et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981—92.</p></div><br />


For citation:


Domashenko M.A., Maksimova M.Y., Korobkova D.Z., Gafarova M.E. Dabigatran experience in primary and secondary prevention of cardioembolic stroke. Neurology, Neuropsychiatry, Psychosomatics. 2013;5(2):69-77. (In Russ.) https://doi.org/10.14412/2074-2711-2013-2417

Views: 488


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)